The US Food and Drug Administration closed out last week with a flurry of oncology approval activity, granting approvals to a new molecular entity from Deciphera Pharmaceuticals Inc., the kinase inhibitor Qinlock, and to new indications for Clovis Oncology Inc.’s PARP inhibitor Rubraca and two Bristol-Myers Squibb Co. products – the dual immunotherapy combination of Opdivo and Yervoy and the thalidomide analog Pomalyst.
BMS also is one of the sponsors that received less-welcome news. The FDA refused to file BMS and bluebird bio Inc